&lt;p&gt;Identification of Potential Metabolite Markers for Middle-Aged Patients with Post-Stroke Depression Using Urine Metabolomics&lt;/p&gt;

Xie, Jing; Han, Yu; Hong, Yueling; Li, Wenwen; Pei, Qilin; Zhou, Xueyi; Zhang, Bingbing; Wang, Ying

doi:10.2147/ndt.s271990

Cited by 12 publications

(7 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Xie et al’s study ( 50 ) included 89 stroke survivors without depression and 92 patients with PSD. A total of 12 differential urinary metabolites were identified between patients with PSD and non-depressed stroke survivors, including hydroxylamine, palmitic acid, glucose, myristic acid, fructose, lactic acid, glyceric acid, azelaic acid, pyroglutamic acid, α-aminobutyric acid, uric acid, and tyrosine.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Does urinary metabolite signature act as a biomarker of post-stroke depression?

et al. 2022

View full text Add to dashboard Cite

BackgroundIt is difficult to conduct the precise diagnosis of post-stroke depression (PSD) in clinical practice due to the complex psychopathology of depressive disorder. Several studies showed that gas chromatography–mass spectrometry (GC-MS)-identified urinary metabolite biomarkers could significantly discriminate PSD from stroke survivors.MethodsA systematic review was performed for the keywords of “urinary metabolite” and “PSD” using Medline, Cochrane Library, Embase, Web of Science, PsycINFO, Wanfang, CNKI, CBM, and VIP database from inception to 31 March 2022.ResultsFour related studies were included in the review. Differential urinary metabolites including lactic acid, palmitic acid, azelaic acid, and tyrosine were identified in all the included studies. As a significant deviation in the metabolite biomarker panel, glyceric acid, azelaic acid, phenylalanine, palmitic acid, pseudouridine, and tyrosine were found in at least 2 included studies, which indicated good potential for the differentiation of PSD.ConclusionThe systematic review provided evidence that differential urinary metabolites analyzed by the GC-MS-based approach might be used as a biomarker for the diagnosis and prognosis of PSD.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Another study found that several specified metabolites could act as predictors of depression recovery (46,47). Of note, recent studies (48)(49)(50)(51) showed that GC-MS-identified urinary metabolite biomarkers could significantly distinguish PSD from stroke survivors, which could be used as an objective diagnostic tool for PSD.…”

Section: Introductionmentioning

confidence: 99%

Does urinary metabolite signature act as a biomarker of post-stroke depression?

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The upregulation of VMA and HVA in urine after stroke observed in this study may indicate the increased activation of the central nervous system leading to the increased breakdown of catecholamines and these metabolites have previously been identified as prognostic biomarkers for stroke [ 24 ]. The metabolite tyrosine is frequently found to be significantly altered in stroke [ 25 , 56 ] and post-stroke depression [ 49 , 50 , 59 ]. While Ormstad et al [ 56 ] argue that tyrosine levels decrease after stroke, other findings suggest that the concentration of tyrosine is increased in the acute phase [ 25 ].…”

Section: Discussionmentioning

confidence: 99%

Unraveling Metabolic Changes following Stroke: Insights from a Urinary Metabolomics Analysis

Petersson,

Bykowski,

Ekstrand

et al. 2024

Metabolites

View full text Add to dashboard Cite

The neuropathological sequelae of stroke and subsequent recovery are incompletely understood. Here, we investigated the metabolic dynamics following stroke to advance the understanding of the pathophysiological mechanisms orchestrating stroke recovery. Using a nuclear magnetic resonance (NMR)-driven metabolomic profiling approach for urine samples obtained from a clinical group, the objective of this research was to (1) identify novel biomarkers indicative of severity and recovery following stroke, and (2) uncover the biochemical pathways underlying repair and functional recovery after stroke. Urine samples and clinical stroke assessments were collected during the acute (2–11 days) and chronic phases (6 months) of stroke. Using a 700 MHz 1H NMR spectrometer, metabolomic profiles were acquired followed by a combination of univariate and multivariate statistical analyses, along with biological pathway analysis and clinical correlations. The results revealed changes in phenylalanine, tyrosine, tryptophan, purine, and glycerophospholipid biosynthesis and metabolism during stroke recovery. Pseudouridine was associated with a change in post-stroke motor recovery. Thus, NMR-based metabolomics is able to provide novel insights into post-stroke cellular functions and establish a foundational framework for future investigations to develop targeted therapeutic interventions, advance stroke diagnosis and management, and enhance overall quality of life for individuals with stroke.

show abstract

“…Several studies have shown that urinary metabolite biomarkers identified by GC-MS can identify post-stroke depression (PSD) in stroke survivors [17]. A biomarker panel consisting of glyceric acid, tyrosine, and azelaic acid was identified in middle-aged and elderly patients with PSD [18,19]. Solid-phase microextraction and GC-MS were used to analyze urinary VOCs and semi-VOCs in patients with late-life major depressive and anxiety disorders.…”

Section: Gc-msmentioning

confidence: 99%

Recent Progress in Mass Spectrometry-Based Metabolomics in Major Depressive Disorder Research

Liu,

Ma,

et al. 2023

Molecules

View full text Add to dashboard Cite

Major depressive disorder (MDD) is a serious mental illness with a heavy social burden, but its underlying molecular mechanisms remain unclear. Mass spectrometry (MS)-based metabolomics is providing new insights into the heterogeneous pathophysiology, diagnosis, treatment, and prognosis of MDD by revealing multi-parametric biomarker signatures at the metabolite level. In this comprehensive review, recent developments of MS-based metabolomics in MDD research are summarized from the perspective of analytical platforms (liquid chromatography-MS, gas chromatography-MS, supercritical fluid chromatography-MS, etc.), strategies (untargeted, targeted, and pseudotargeted metabolomics), key metabolite changes (monoamine neurotransmitters, amino acids, lipids, etc.), and antidepressant treatments (both western and traditional Chinese medicines). Depression sub-phenotypes, comorbid depression, and multi-omics approaches are also highlighted to stimulate further advances in MS-based metabolomics in the field of MDD research.

show abstract

<p>Identification of Potential Metabolite Markers for Middle-Aged Patients with Post-Stroke Depression Using Urine Metabolomics</p>

Cited by 12 publications

References 30 publications

Does urinary metabolite signature act as a biomarker of post-stroke depression?

Does urinary metabolite signature act as a biomarker of post-stroke depression?

Unraveling Metabolic Changes following Stroke: Insights from a Urinary Metabolomics Analysis

Recent Progress in Mass Spectrometry-Based Metabolomics in Major Depressive Disorder Research

Contact Info

Product

Resources

About